The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Hisamitsu Pharmaceutical Co's current ratio for the quarter that ended in Nov. 2025 was 3.77.
Hisamitsu Pharmaceutical Co has a current ratio of 3.77. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Current Ratio or its related term are showing as below:
FSE:4530'
s Current Ratio Range Over the Past 10 Years
Min: 4.08 Med: 5.21 Max: 6.59
Current: 4.08
During the past 13 years, Hisamitsu Pharmaceutical Co's highest Current Ratio was 6.59. The lowest was 4.08. And the median was 5.21.
FSE:4530's Current Ratio is ranked better than 78.86% of 998
companies
in the Drug Manufacturers industry
Industry Median: 1.995
vs FSE:4530: 4.08
Hisamitsu Pharmaceutical Co (FSE:4530) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Hisamitsu Pharmaceutical Co Current Ratio Related Terms
Hisamitsu Pharmaceutical Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Current Ratio of 3.77 as of Nov. 2025. This is 28% below median its historical median of 5.21. Over the past decade, Hisamitsu Pharmaceutical Co's Current Ratio has ranged from 4.08 to 6.59. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #211 out of 998 companies in the Drug Manufacturers industry, placing it in the top 21.1%.
Is Hisamitsu Pharmaceutical Co's Current Ratio too high?
Hisamitsu Pharmaceutical Co's current Current Ratio of 3.77 is 28% below median its 10-year median of 5.21. Over the past 10 years, this metric has ranged from a low of 4.08 to a high of 6.59. The Drug Manufacturers industry median Current Ratio is 2.00. Hisamitsu Pharmaceutical Co's value of 3.77 is 89% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #211 out of 998 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #211 out of 998 companies for Current Ratio. This places Hisamitsu Pharmaceutical Co in the top 21% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Hisamitsu Pharmaceutical Co's value of 3.77 is 89% above this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Current Ratio has ranged from 4.08 to 6.59 over the past decade. While the company's 10-year median is 5.21 vs. the industry median of 2.00, Hisamitsu Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Current Ratio of 3.77 is 89% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Current Ratio is 3.77, which is 28% below median its own 10-year median of 5.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Current Ratio of 3.77. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Current Ratio is 3.77, which is 28% below median its 10-year median of 5.21 and 89% above the Drug Manufacturers industry median of 2.00. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Current Ratio is 3.77 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Current Ratio: 3.77 (28% below median its 10-year median of 5.21)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 89% above the Drug Manufacturers median (#211 of 998)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
